Intrathecal Baclofen Therapy for Refractory Spasticity: A Case Series

Area of Science:

• Neurology
• Pharmacology
• Rehabilitation Medicine

Background:

• Refractory spasticity presents significant clinical management challenges.
• Intrathecal baclofen (ITB) therapy offers a promising treatment approach for refractory spasticity.
• Evaluating ITB therapy's efficacy in managing refractory spasticity symptoms is essential.

Purpose of the Study:

• To assess the effectiveness of Intrathecal baclofen (ITB) therapy in patients with refractory spasticity.
• To identify key outcomes related to pain, mobility, spasm frequency, and spasticity alleviation.

Main Methods:

• A retrospective chart review of 34 patients with refractory spasticity undergoing ITB therapy.
• Data collection included patient demographics, clinical characteristics, and administered dosages.
• Primary outcomes measured were pain reduction, mobility improvement, spasm frequency decrease, and spasticity alleviation.

Main Results:

• ITB therapy demonstrated significant reductions in pain and spasm frequency.
• Improvements in patient mobility and overall spasticity were observed.
• The mean daily ITB dose was 245 μg, but effective dosage was patient-specific and time-sensitive, with side effects linked to incorrect administration.

Conclusions:

• Intrathecal baclofen (ITB) therapy is an effective and safe treatment for refractory spasticity.
• Individualized dosing and close monitoring are critical to optimize ITB therapy outcomes and prevent adverse events.
• Careful consideration of risks and benefits is paramount when prescribing ITB therapy for refractory spasticity.